Results 91 to 100 of about 18,081 (213)

Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation [PDF]

, 2023
Malini Gandhi, Kim-Lien Nguyen, Jordan E. Lake, Dan Liao, Aleen Khodabakhshian, Mario Guerrero, Chrisandra Shufelt, C. Noel Bairey Merz, Wilbert Jordan, Eric S. Daar, Debika Bhattacharya, Kara W Chew   +11 more
openalex   +1 more source

Repurposing an endogenous degradation domain for antibody-mediated disposal of cell-surface proteins

EMBO Reports
The exquisite specificity of antibodies can be harnessed to effect targeted degradation of membrane proteins. Here, we demonstrate targeted protein removal utilising a protein degradation domain derived from the endogenous human protein Proprotein ...
Janika Schmitt, Emma Poole, Ian Groves, David J Owen, Stephen C Graham, John Sinclair, Bernard T Kelly   +6 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations

Frontiers in Pharmacology
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is primarily secreted by hepatocytes. PCSK9 is critical in liver low-density lipoprotein receptors (LDLRs) metabolism.
Fengyuan Lu, En Li, Xiaoyu Yang, Xiaoyu Yang   +3 more
doaj   +1 more source

The Proprotein Convertase PC7 [PDF]

Journal of Biological Chemistry, 2011
Estelle Rousselet, Suzanne Benjannet, Josée Hamelin, Maryssa Canuel, Nabil G. Seidah   +4 more
openaire   +1 more source

Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study

Drugs - Real World Outcomes
Background Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target.
Klaus G. Parhofer, Peter Bramlage, Constanze Gries, Cornelia Harder, Christiane Look, W. Dieter Paar, Ursula Rauch-Kröhnert   +6 more
doaj   +1 more source

Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events [PDF]

, 2015
Paul M. Ridker, Nader Rifai, Gary Bradwin, Lynda M. Rose   +3 more
openalex   +1 more source

Proprotein convertase subtilisin and kexin type 9 in Sub Clinical Hypothyroidism as a Risk Factor for Cardiovascular Disease

, 2022
Media Salih, Sherwan Salih, Ahmed Salih, W Alborn, G Cao, H Careskey, Y Qian, D Subramaniam, J Davies, E Conner, R Konrad, B Biondi, A Cappola, D Cooper, G Cai, G Shi, S Xue, W Lu, D Cooper, Jesus De, J Garduno-Garcia, U Alvirde-Garcia, G Lopez-Carrasco, M Padilla Mendoza, R Mehta, O Arellano-Campos, R Choza, L Sauque, M Garay-Sevilla, J Malacara, A Delitala, G Fanciulli, M Maioli, G Delitala, M Denis, J Marcinkiewicz, A Zaid, D Gauthier, S Poirier, C Lazure, N Seidah, A Prat, L Duntas, L Wartofsky, M Ejaz, P Kumar, M Thakur, P Bachani, S Naz, K Lal, W Shahid, S Shahid, M Jahangir, A Rizwan, C Erem, B Ference, J Robinson, R Brook, A Catapano, M Chapman, D Neff, S Voros, R Giugliano, G Davey Smith, S Fazio, Y Gong, Y Ma, Z Ye, Z Fu, P Yang, B Gao, W Guo, D Hu, J Ye, S Ma, R Harvey, D Ferrier, J Horton, ) Cohen, J Hobbs, H, T Jacobson, M Ito, K Maki, C Orringer, H Bays, P Jones, J Mckenney, S Grundy, E Gill, R Wild, D Wilson, W Brown, R Kc, S Khatiwada, K Deo Mehta, P Pandey, M Lamsal, S Majhi, J Kvetny   +99 more
openalex   +2 more sources

Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice

Respiratory Research
Background Obesity is associated with airway hyperresponsiveness and lung fibrosis, which may reduce the effectiveness of standard asthma treatment in individuals suffering from both conditions.
Lin Liang, Sook In Chung, Tae-Eun Guon, Kyung Hee Park, Jae-Hyun Lee, Jung-Won Park   +5 more
doaj   +1 more source

Bone Morphogenetic Protein-1 Processes the NH2-terminal Propeptide, and a Furin-like Proprotein Convertase Processes the COOH-terminal Propeptide of pro-α1(V) Collagen

, 1998
Yasutada Imamura, Barry M. Steiglitz, Daniel S. Greenspan   +2 more
openalex   +1 more source

Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia　― A Post-Marketing Survey (J-POSSIBLE) ―

, 2023
Arihiro Kiyosue, Satoshi Yasuda, Akiyoshi Tomura, Makiko Usami, Hidenori Arai   +4 more
openalex   +2 more sources